Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
NCT03644550 · National Cancer Institute (NCI) · PHASE2 · terminated · last registry update 2021-12-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to the Food and Drug Administration's recent approval of Nivolumab plus Ipilimumab as first line treatment for Mesothelioma, the principal investigator decided to end the study early (prior to reaching enrollment goal).” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MSLN within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-09-22Results posted on the registry: Morphotek, MORAb-009 (Amatuximab) + Pemetrexed (NCT00738582)
- 2022-08-23Results posted on the registry: National Cancer Institute (NCI), LMB-100 + nab-paclitaxel (NCT02798536)
- 2022-02-08Results posted on the registry: National Cancer Institute (NCI), LMB-100 + Tofacitinib (NCT04034238)
- 2021-02-02Results posted on the registry: National Cancer Institute (NCI), LMB-100 + Nab-Paclitaxel (NCT02810418)
- 2021-01-22Results posted on the registry: Yale University, anetumab ravtansine (NCT03023722)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision